-
The Power of Lombardi Care
Jaime Posada was diagnosed with stage 4 lung cancer and given two to six months to live. That was in 2017, before he came to Georgetown Lombardi. Hear Posada’s compelling story.
Category: Special Stories
-
Two Undergraduates Working in Georgetown Lombardi Labs Receive Goldwater Scholarships
Dua Mobin (C’25), who works in the Braselmann Lab, and Morgan Rice (C’25), who works in the Riggins Lab, were named 2024 Goldwater Scholars. One of the most prestigious awards for undergraduates in science, technology, engineering and math, the Goldwater Scholarship is given to support and cultivate the next generation of scientists, researchers and engineers.
Category: Lombardi Stories
-
Hackensack Meridian John Theurer Cancer Center Treats its First Patient in Innovative Cell Therapy Clinical Trial
Researchers at Hackensack Meridian John Theurer Cancer Center — part of the National Cancer Institute-designated Lombardi Comprehensive Cancer Center at Georgetown University —treated its first patient at the Center in a cutting-edge phase I clinical trial of LYL845, a novel cellular therapy under evaluation for advanced melanoma and other select solid tumors. A type of tumor-infiltrating lymphocyte (TIL) therapy, LYL845 is custom-made from a patient’s cells and designed to help the immune system find and kill cancer cells.
Category: Lombardi Stories
-
John Theurer Cancer Center Physician Co-Authors Clinical Research on Innovative Oral Leukemia Therapy
Researchers at Hackensack Meridian’s John Theurer Cancer Center are part of a published Phase 3 study reporting on the equivalent safety and effectiveness in the oral treatment of blood cancers, such as myelodysplastic syndrome and/or chronic myelomonocytic leukemia, to its previously inpatient, intravenous treatment counterparts. John Theurer Cancer Center is part of the NCI-designated Lombardi Comprehensive Cancer Center at Georgetown University.
Category: Lombardi Stories
-
John Theurer Cancer Center Physician Co-Authors Clinical Research on mRNA Vaccine Intervention Benefits in High-Risk Melanoma
Researchers at Hackensack University Medical Center’s John Theurer Cancer Center (JTCC), a part of the NCI-designated Lombardi Comprehensive Cancer Center at Georgetown University, reported on a novel mRNA vaccine’s delivering improved survival rates in Stage IIIB and IV (metastatic) skin cancer, as part of an ongoing joint-study.
Category: Lombardi Stories
-
Tumor Biology Program Student Advocates for More Deaf and Hard-of-Hearing Scientists
Megan Majocha (G’24) finds herself on a dual mission. As a PhD student conducting breast cancer research, she wants to contribute to the understanding of what drives a specific type of cancer to spread. But as a scientist in the making, Majocha, who is deaf, also wants to make sure the path to becoming a researcher is smoother for kids who grew up just like her.
Category: Lombardi Stories
-
Drug Found to be Effective in Difficult to Treat Autoimmune Blood Disorder
Category: News Release
-
Hands-on Healing
Category: Lombardi Stories
-
Ralph Lauren Corporate Foundation Makes Gift to Address Disparities in Cancer Care
Category: Lombardi Stories
-
St. Baldrick’s Event Organizers Motivated by Personal Connections with Pediatric Cancer
Category: Lombardi Stories
